efavirenz FDA Link

HIV-1 reverse transcriptase inhibitor

Also Known As:

Sustiva; (s)- 6- chloro- 4- cyclopropylethynyl- 4- trifluoromethyl- 1,4- dihydro- 2H- 3,1- benzoxazin- 2- one; DMP 266; DMP-266; L 743,726; L 743726; L-743,726; L-743726; Stocrin; efavirenz, (R)-isomer; efavirenz, (S)-isomer

Pharmalogical Action Categories:

D018894 - Reverse Transcriptase Inhibitors
D065688 - Cytochrome P-450 CYP2C9 Inhibitors
D065689 - Cytochrome P-450 CYP2C19 Inhibitors
D065695 - Cytochrome P-450 CYP2B6 Inducers
D065701 - Cytochrome P-450 CYP3A Inducers

Organic Chemicals: 140
- Hydrocarbons: 1726
  - Cyclic Hydrocarbons: 96
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclopropanes: 9
        efavirenz: 1118
  - Acyclic Hydrocarbons
    - Alkynes: 227
      - efavirenz: 1118
Heterocyclic Compounds: 207
- 1-Ring Heterocyclic Compounds
  - Oxazines: 10
    - Benzoxazines: 59
      - efavirenz: 1118
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzoxazines: 59
      - efavirenz: 1118

Phumla Zuleika Sinxadi Selected Research

Phumla Zuleika Sinxadi Research Topics

Disease

Drug/Important Bio-Agent (IBA)

Therapy/Procedure